A new brand called Elevant has launched an NMN supplement to support cellular health
Elevant, a brand of the Swiss biotech company Seneque, recently launched Prime capsules in the U.S. Prime is a clinically tested, high purity form of nicotinamide mononucleotide (NMN), a precursor of NAD+ (nicotinamide adenine dinucleotide).
Image courtesy of Elevant
Elevant (New York, NY), a brand of the Swiss biotech company Seneque, recently launched Prime capsules in the U.S. Prime is a clinically tested, high purity form of nicotinamide mononucleotide (NMN), a precursor of NAD+ (nicotinamide adenine dinucleotide). The high purity NMN, called NMN-C, is self-affirmed GRAS (generally recognized as safe) as of November 2020 after an independent panel of toxicology and nutrition experts rigorously evaluated research studies and toxicology data to conclude NMN-C was not harmful under its intended use: UL of 2.2 mg/lb for humans, or 300 mg for a 135-lb adult.
To further transparency, the results of a recent OECD 408 toxicology study on NMN-C were published. According to Elevant, this was a first of its kind study to be undertaken on NMN, analyzing the ingredient’s No Observable Adverse Effect Level (NOAEL). The company is also partnering with leading European and American institutions such as the Buck Institute for Research on Aging for preclinical research exploring the health benefits of NMN, and to propel further development of NMN-C to support cardiovascular, cognitive, muscular, skin, and immune health.
Prime is sold by Elevant directly to consumers and offers an annual subscription.
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
